3d agoGuruFocusBULLISH 63Analyst
Archived explainer. For the current picture see today's TNGX page.
Why Is TANGO THERAPEUTICS I (TNGX) Stock Up Today?
By the Top Tier Newswire AI Desk · November 11, 2026 at 7:04 AM ET · reviewed against 5 wire stories
TANGO THERAPEUTICS I (TNGX) is up +6.86% in the latest session. Our newswire has captured 5 stories on TNGX across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Tango Therapeutics (TNGX) shares rose 6.86% to $24.30, driven by strong clinical data and a cluster of analyst upgrades. The primary catalyst was the presentation of promising Phase 1/2 results for the combination of vopimetostat and daraxonrasib at the 2026 ESMO Congress.
What Happened
The company reported third quarter 2026 financial results, highlighting that the combination study demonstrated an 82% objective response rate. This clinical milestone prompted several investment banks to adjust their valuations. JPMorgan maintained an Overweight rating and raised its price target to $47.00, citing the pipeline. Jefferies also raised its price target on the trial data. In contrast, Wedbush maintained an Outperform rating but lowered its price target to $40. HC Wainwright & Co. maintained a Buy rating while lowering its price target to $67.
What The Data Shows
The stock opened at $24.80, representing a 2.1% gap from the prior close of $24.30. The session high was $24.80 at 7:00 AM ET, while the session low was $24.25 at the same time. The last trade was $24.25. Volume so far is 0.0M shares, which is 0.0x the 3-month daily average. Fundamentals show a market cap of $3.9B. The company is unprofitable with a trailing twelve months EPS of -1.38. Revenue is -100.0% TTM, and the net margin is -229.9%. The beta is 1.22. The 52-week range is $7.49 to $34.39. Over the last 8 sessions, the stock moved 4.3%, from $25.85 to $26.95. The 52-week tape printed 17 fresh 52-week highs and 1 fresh 52-week low on 2026-11-10. Recent insider filings show 0 buys and 5 sells totaling $1.7M in the last 90 days. Jessica Newcomb, Principal Accounting Officer, sold on 2026-11-02. Adam Crystal, President of Research and Development, sold on 2026-11-02 and 2026-10-01.
What To Watch
Analyst coverage remains active with five stories from three sources in the last 36 hours. Investors will monitor how the market digests the 82% objective response rate and the varying price targets from major banks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TNGX by the numbers
Last: $24.30Session: +6.86%7 sessions: +4.27%Coverage: 5 stories / 3 sourcesAI sentiment: 57/100 (mixed)Mkt cap: $3.9B52w: $7.49 to $34.39
The headlines behind the move
3d agoGuruFocusBEARISH 42Analyst
TNGX Maintained by Wedbush -- Price Target Lowered to $40
3d agoInvesting.com Analyst RatingsBULLISH 64Analyst
Jefferies raises Tango Therapeutics stock price target on trial data
Jefferies raises Tango Therapeutics stock price target on trial data
3d agoInvesting.com Analyst RatingsBULLISH 64Analyst
JPMorgan raises Tango Therapeutics price target to $47 on pipeline
JPMorgan raises Tango Therapeutics price target to $47 on pipeline
4d agoGlobeNewswireNEUTRAL 52Earnings
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on TNGX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TNGX move explainers: 2026-11-11 · 2026-10-23